logo-loader
RNS
Science Group PLC

Science Group PLC - AGM Trading Update and Capital Allocation

RNS Number : 9808E
Science Group PLC
20 May 2026
 

 

20 May 2026

 

Science Group plc

(the "Group" or "Science Group")

 

AGM Trading Update and Capital Allocation

 

Science Group is an international services and systems company delivering innovation through the application of science, technology & engineering. The Group's primary performance metrics are : adjusted operating profit, operating margin and cash flow.

 

Group Trading Update

 

Despite geopolitical events impacting customer confidence, and the widely-reported challenges in UK defence contracting, Science Group remains on track to deliver another resilient performance for 2026, in line with the Board's expectations. As anticipated, revenue in the year is expected to be lower than the prior year, primarily due to the reductions in previously-reported, low margin activities in the Defence sector, offset by margin improvement.

 

After returning over £24 million to shareholders since the 2025 AGM (share buybacks and dividend outflows), at 30 April 2026, Science Group had Group cash of £68.5 million and net funds of £57.2 million (30 April 2025: £20.9 million and net funds of £9.0 million). The Group's revolving credit facility (£30m + £10m accordion, expiring in 2030) remains undrawn.

 

Operating Business Overview

 

The Sagentia Services Division operates across multiple sectors, including MedTech, Consumer, Food & Beverage, Defence and Industrial markets. While most areas have experienced some indirect effects of the recent geopolitical instability, the UK Defence sector has been more challenging due to the delays in contracting associated with the deferral of the UK Defence Investment Plan. Nevertheless, the Sagentia Division overall remains well positioned for 2026.

 

The characteristics of the CMS2 business, providing systems to critical operational submarine programmes, have meant that the core business (excluding the irregular, low margin consumables orders) has been less affected by the UK Defence sector budget uncertainty. Furthermore, in recent months CMS2 has progressed UK contracts which, if successfully concluded, would position the business for growth and provide visibility into the 2030's. Further details will be provided if/when appropriate.

 

The Frontier core DAB+/SmartRadio revenue continues to be relatively stable, although product mix has varied. Shipments of Auria, the new connected audio solution, commenced in April and products should be available to consumers in limited volume in late summer. The business however remains cautious due to potential end-market price inflation driven by memory chip costs and the discretionary nature of consumer electronics expenditure in a weak economic climate.

 

 Capital Allocation

 

At the AGM in May 2025, shareholders approved the standard buy-back resolution and 3,938,596 shares in the company have been repurchased in the past year, equivalent to 8.8% of the share capital at the time of the 2025 AGM. At 19 May 2026, the Company has 41,004,593 shares in issue (excluding treasury shares), which is a lower voting share capital than at the AGM 15 years ago confirming that the significant growth of the Group, the balance sheet strength and the accumulated cash have been achieved through organic cash flow. The Board anticipates continuing the buy-back programme in the year ahead and at the 2026 AGM, to be held today, has invited shareholders to consider increasing the buy-back limit to provide additional flexibility if appropriate.

 

Science Group's balance sheet provides a solid foundation for the operating businesses and enables the Board to pursue M&A/investment opportunities to enhance shareholder value when appropriate. However, the Group's relative valuation as a London-listed company remains a constraint on the corporate ambition. Accordingly, the Board continues to consider all capital allocation options including, in the absence of material corporate/investment activity, a potential increase in the return of capital to shareholders from the Group's existing cash resources.

 

 

- Ends -

 

 

 

For further information:

Science Group plc


Martyn Ratcliffe, Executive Chair

Tel: +44 (0) 1223 875 200

Jon Brett, Finance Director

www.sciencegroup.com 

 

Panmure Liberum Limited (Nomad & Joint Broker)                           

Nicholas How, Rupert Dearden

 

Peel Hunt LLP (Joint Broker)                                                                 

Neil Patel, Benjamin Cryer, Kate Bannatyne

 

 

Tel: +44 (0)20 3100 2000

 

 

Tel: +44 (0)20 7418 8900

 

 






 



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUACAUPQGQB
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Transaction in Own Shares

3 days, 6 hours ago

Holding(s) in Company

1 week, 3 days ago

Transaction in Own Shares

1 week, 3 days ago

Change to buyback reporting

2 weeks, 3 days ago

Total Voting Rights

2 weeks, 3 days ago

Transaction in Own Shares

3 weeks, 1 day ago

Transaction in Own Shares

3 weeks, 2 days ago

4 min read